Guatemala vs Tunisia: Average cost of drugs for extensively drug-resistant tuberculosis
Guatemala
11,910 constant 2022 US$
in 2024
Tunisia
40,560 constant 2022 US$
in 2023
Guatemala rank
3rd
Tunisia rank
1st
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Guatemala
- Tunisia
How they compare
Tunisia currently reports 40,560 constant 2022 US$ against 11,910 constant 2022 US$ in Guatemala, a difference of 28,650 constant 2022 US$.
That makes Tunisia's figure about 3.4 times Guatemala's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Guatemala ahead.
Guatemala ranks 3rd and Tunisia ranks 1st of 56 countries.
Across the 2 decades both report, Guatemala averaged higher in 1 and Tunisia in 1.
Head to head by decade
| Decade | Guatemala | Tunisia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 11,075 constant 2022 US$ | 7,000 constant 2022 US$ | 4,075 constant 2022 US$ | Guatemala |
| 2020s | 4,509 constant 2022 US$ | 20,440 constant 2022 US$ | 15,931 constant 2022 US$ | Tunisia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Guatemala or Tunisia?
- Tunisia, at 40,560 constant 2022 US$ against 11,910 constant 2022 US$ in Guatemala as of 2023.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Guatemala and Tunisia?
- 28,650 constant 2022 US$, with Tunisia ahead.
- How many years of comparable data are there for Guatemala and Tunisia?
- 5 years are reported by both, from 2017 to 2023.
- How do Guatemala and Tunisia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Guatemala ranks 3rd and Tunisia ranks 1st of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.